Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 11, 2025
Reporting period
Not applicable
Filed with the SEC
Jan 21, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001869391-26-000007
Filed / recorded
Jan 21, 2026, 9:04 PM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
SPRUCE BIOSCIENCES, INC.
Issuer CIK
1683553
Ticker
SPRB
Reporting person
Douglas Kirk Ways
Relationship
Director, Officer
Officer title
Interim Chief Medical Officer
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
Dec 11, 2025
Transaction code
A
Shares / units
5,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
5,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each RSU represents a contingent right to receive one share of common stock of the Issuer.
25% of the total number of restricted stock units ("RSUs") vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date.